Checkpoint inhibitors currently approved by the US Food and Drug Administration (FDA) target the cytotoxic T-lymphocyte–associated protein 4 (CTLA-4), programmed cell death receptor 1 (PD-1), or programmed cell death ligand 1 (PD-L1) and work by preventing immune evasion from cancer cells. Here, CD274 is linked to cancer.